Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Advanced Preventive Women's Clinic For Women With Menopause Symptoms Who Are At Risk For Heart Disease
Women who are at risk for heart disease and who are also experiencing menopause symptoms now have an added re a highly specialized clinic in the Division of Cardiology at the Cedars-Sinai Heart Institute. The Advanced Preventive Women"s Clinic at the Women"s Heart Center recently opened and is offering comprehensive cardiac risk assessments designed specifically for women who are in menopause. The clinic also offers menopausal patients state-of-the-art screenings, as well as personalized medicine therapies and counseling, including high-risk hormone counseling.
generic viagra online
Today's Selection Of Opinions And Editorials
Comparative-Effectiveness Research - Implications of the Federal Coordinating Council"s Report The New England Journal Of Medicine
News of the day
2009/039 NICE Guidance Recommends Lenalidomide For Multiple Myeloma
The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of lenalidomide for multiple myeloma in people who have received at least one prior therapy.
Public Health

InteKrin Therapeutics To Present At The 2009 American Diabetes Association Annual Meeting

InteKrin Therapeutics, Inc. announced it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapies in Development in Humans" session at 4:00 pm CDT. Dr. Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, will provide a summary of the latest clinical data supporting the design of INT131 to safely and effectively address insulin resistance in a presentation entitled "INT131: Significantly Lowers Glucose Without Typical Thiazolidinedione (TZD) Side Effects in Patients with Type 2 Diabetes." About INT131 INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Purposefully designed as a SPPARM, INT131 selectively modulates PPAR-gamma, thereby allowing the retention of the clinically proven anti-diabetic efficacy of PPAR gamma activation, while mitigating or eliminating the well recognized side effects of TZD full PPAR gamma agonists rosiglitazone and pioglitazone (Avandia(R) and Actos(R) respectively). About InteKrin InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin"s business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin"s team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders. InteKrin Therapeutics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009